KR20080068146A - M-csf에 대한 항체 - Google Patents
M-csf에 대한 항체 Download PDFInfo
- Publication number
- KR20080068146A KR20080068146A KR1020087015841A KR20087015841A KR20080068146A KR 20080068146 A KR20080068146 A KR 20080068146A KR 1020087015841 A KR1020087015841 A KR 1020087015841A KR 20087015841 A KR20087015841 A KR 20087015841A KR 20080068146 A KR20080068146 A KR 20080068146A
- Authority
- KR
- South Korea
- Prior art keywords
- ser
- amino acid
- seq
- antibody
- acid sequence
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/06—Buying, selling or leasing transactions
- G06Q30/0601—Electronic shopping [e-shopping]
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q40/00—Finance; Insurance; Tax strategies; Processing of corporate or income taxes
- G06Q40/04—Trading; Exchange, e.g. stocks, commodities, derivatives or currency exchange
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for specific business sectors, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/12—Hotels or restaurants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
조건 | 스피너 1 | 스피너 2 |
접종 밀도(1X106세포/ml) | 0.16 ml | 0.16 ml |
하이브리도마 무혈청 배지(지브코 cat# 12045-076) | 나머지 | 나머지 |
극히 낮은 IgG 혈청(지브코 cat# 16250-078 | 5% | 5% |
L-글루타민(JRH 바이오사이언스 cat# 59202-500M | 8 mmol/L | 8 mmol/L |
비필수 아미노산 (지브코 cat# 11140-050) | 1% | 1% |
펩톤 (디프코 cat# 211693) | 1g/L | 1g/L |
2M 글루코스 (JT 베이커 cat# 1920-07로부터 제조된 회사내 저장용액) | 8g/L | 8g/L |
항-발포 C (시그마 cat# A-8011) | 1m/L | 1m/L |
Claims (34)
- M-CSF에 특이적으로 결합하는 인간 모노클로날 항체 또는 이의 항원-결합 부위.
- 제1항에 있어서,a) M-CSF의 인간 분비 이소체(isoform) 및 M-CSF의 막 결합 이소체에 결합하는 특성;b) GM-CSF 또는 G-CSF에 대한 선택성보다 100배 이상 더 높은 M-CSF에 대한 선택성을 가지는 특성;c) 1.0 x 10-7 M 이하의 KD로 M-CSF에 결합하는 특성;d) 2.0 x 10-4s-1 이하의 M-CSF에 대한 해리 속도(koff)를 가지는 특성; 또는e) 인간 c- fms의 존재하에서 인간 M-CSF에 결합하는 특성중 적어도 하나의 특성을 보유하는 인간 모노클로날 항체 또는 이의 항원-결합 부위.
- 제2항에 있어서, c- fms와의 결합을 차단하고 1.0 x 10-7 M 이하의 KD로 M-CSF에 결합하는 인간 모노클로날 항체 또는 이의 항원-결합 부위.
- M-CSF에 특이적으로 결합하는 인간 모노클로날 항체 8.10.3F 또는 이의 항원-결합 부위.
- M-CSF에 특이적으로 결합하는 인간 모노클로날 항체 9.14.4I 또는 이의 항원-결합 부위.
- a) M-CSF에 결합하기 위해 항체 252, 88, 100, 3.8.3, 2.7.3, 1.120.1, 9.14.4I, 8.10.3F, 9.7.2IF, 9.14.4, 8.10.3, 9.7.2, 9.7.2C-Ser, 9.14.4C-Ser, 8.10.3C-Ser, 8.10.3-CG2, 9.7.2-CG2, 9.7.2-CG4, 9.14.4-CG2, 9.14.4-CG4, 9.14.4-Ser, 9.7.2-Ser, 8.10.3-Ser, 8.10.3-CG4, 8.10.3FG1 및 9.14.4G1로 구성되는 군으로부터 선택되는 항체와 교차-경쟁하는 특성;b) M-CSF에 결합하기 위하여 항체 252, 88, 100, 3.8.3, 2.7.3, 1.120.1, 9.14.4I, 8.10.3F, 9.7.2IF, 9.14.4, 8.10.3, 9.7.2, 9.7.2C-Ser, 9.14.4C-Ser, 8.10.3C-Ser, 8.10.3-CG2, 9.7.2-CG2, 9.7.2-CG4, 9.14.4-CG2, 9.14.4-CG4, 9.14.4-Ser, 9.7.2-Ser, 8.10.3-Ser, 8.10.3-CG4, 8.10.3FG1 및 9.14.4G1로 구성되는 군으로부터 선택되는 항체와 경쟁하는 특성;c) 항체 252, 88, 100, 3.8.3, 2.7.3, 1.120.1, 9.14.4I, 8.10.3F, 9.7.2IF, 9.14.4, 8.10.3, 9.7.2, 9.7.2C-Ser, 9.14.4C-Ser, 8.10.3C-Ser, 8.10.3-CG2, 9.7.2-CG2, 9.7.2-CG4, 9.14.4-CG2, 9.14.4-CG4, 9.14.4-Ser, 9.7.2-Ser, 8.10.3- Ser, 8.10.3-CG4, 8.10.3FG1 및 9.14.4G1로 구성되는 군으로부터 선택되는 항체와 동일한 M-CSF의 에피토프에 결합하는 특성;d) 항체 252, 88, 100, 3.8.3, 2.7.3, 1.120.1, 9.14.4I, 8.10.3F, 9.7.2IF, 9.14.4, 8.10.3, 9.7.2, 9.7.2C-Ser, 9.14.4C-Ser, 8.10.3C-Ser, 8.10.3-CG2, 9.7.2-CG2, 9.7.2-CG4, 9.14.4-CG2, 9.14.4-CG4, 9.14.4-Ser, 9.7.2-Ser, 8.10.3-Ser, 8.10.3-CG4, 8.10.3FG1 및 9.14.4G1로 구성되는 군으로부터 선택되는 항체와 실질적으로 동일한 KD로 M-CSF에 결합하는 특성; 및e) 항체 252, 88, 100, 3.8.3, 2.7.3, 1.120.1, 9.14.4I, 8.10.3F, 9.7.2IF, 9.14.4, 8.10.3, 9.7.2, 9.7.2C-Ser, 9.14.4C-Ser, 8.10.3C-Ser, 8.10.3-CG2, 9.7.2-CG2, 9.7.2-CG4, 9.14.4-CG2, 9.14.4-CG4, 9.14.4-Ser, 9.7.2-Ser, 8.10.3-Ser, 8.10.3-CG4, 8.10.3FG1 및 9.14.4G1로 구성되는 군으로부터 선택되는 항체와 실질적으로 동일한 해리 속도로 M-CSF에 결합하는 특성으로 구성된 군으로부터 선택되는 특성 중 하나 이상을 가지는, 인간 M-CSF에 특이적으로 결합하여 이를 억제하는 인간화 항체, 키메라 항체 또는 인간 모노클로날 항체 또는 이의 항원-결합 부위.
- a) 시그널 서열 없이, 서열 번호 2에 기재된 중쇄 아미노산 서열 및 서열 번호 4에 기재된 경쇄 아미노산 서열을 포함하는 항체;b) 시그널 서열 없이, 서열 번호 6에 기재된 중쇄 아미노산 서열 및 서열 번 호 8에 기재된 경쇄 아미노산 서열을 포함하는 항체;c) 시그널 서열 없이, 서열 번호 10에 기재된 중쇄 아미노산 서열 및 서열 번호 12에 기재된 경쇄 아미노산 서열을 포함하는 항체;d) 시그널 서열 없이, 서열 번호 14에 기재된 중쇄 아미노산 서열 및 서열 번호 16에 기재된 경쇄 아미노산 서열을 포함하는 항체;e) 시그널 서열 없이, 서열 번호 18에 기재된 중쇄 아미노산 서열 및 서열 번호 20에 기재된 경쇄 아미노산 서열을 포함하는 항체;f) 시그널 서열 없이, 서열 번호 22에 기재된 중쇄 아미노산 서열 및 서열 번호 24에 기재된 경쇄 아미노산 서열을 포함하는 항체;g) 시그널 서열 없이, 서열 번호 26에 기재된 중쇄 아미노산 서열 및 서열 번호 28에 기재된 경쇄 아미노산 서열을 포함하는 항체;h) 시그널 서열 없이, 서열 번호 38에 기재된 중쇄 아미노산 서열 및 서열 번호 28에 기재된 경쇄 아미노산 서열을 포함하는 항체;i) 시그널 서열 없이, 서열 번호 54에 기재된 중쇄 아미노산 서열 및 서열 번호 56에 기재된 경쇄 아미노산 서열을 포함하는 항체;j) 시그널 서열 없이, 서열 번호 74에 기재된 중쇄 아미노산 서열 및 서열 번호 56에 기재된 경쇄 아미노산 서열을 포함하는 항체;k) 시그널 서열 없이, 서열 번호 78에 기재된 중쇄 아미노산 서열 및 서열 번호 56에 기재된 경쇄 아미노산 서열을 포함하는 항체;l) 시그널 서열 없이, 서열 번호 82에 기재된 중쇄 아미노산 서열 및 서열 번호 28에 기재된 경쇄 아미노산 서열을 포함하는 항체;m) 시그널 서열 없이, 서열 번호 102에 기재된 중쇄 아미노산 서열 및 서열 번호 28에 기재된 경쇄 아미노산 서열을 포함하는 항체;n) 시그널 서열 없이, 서열 번호 30에 기재된 중쇄 아미노산 서열 및 서열 번호 32에 기재된 경쇄 아미노산 서열을 포함하는 항체;o) 시그널 서열 없이, 서열 번호 30에 기재된 중쇄 아미노산 서열 및 서열 번호 44에 기재된 경쇄 아미노산 서열을 포함하는 항체;p) 시그널 서열 없이, 서열 번호 58에 기재된 중쇄 아미노산 서열 및 서열 번호 60에 기재된 경쇄 아미노산 서열을 포함하는 항체;q) 시그널 서열 없이, 서열 번호 62에 기재된 중쇄 아미노산 서열 및 서열 번호 60에 기재된 경쇄 아미노산 서열을 포함하는 항체;r) 시그널 서열 없이, 서열 번호 90에 기재된 중쇄 아미노산 서열 및 서열 번호 44에 기재된 경쇄 아미노산 서열을 포함하는 항체;s) 시그널 서열 없이, 서열 번호 94에 기재된 중쇄 아미노산 서열 및 서열 번호 60에 기재된 경쇄 아미노산 서열을 포함하는 항체;t) 시그널 서열 없이, 서열 번호 98에 기재된 중쇄 아미노산 서열 및 서열 번호 32에 기재된 경쇄 아미노산 서열을 포함하는 항체;u) 시그널 서열 없이, 서열 번호 34에 기재된 중쇄 아미노산 서열 및 서열 번호 36에 기재된 경쇄 아미노산 서열을 포함하는 항체;v) 시그널 서열 없이, 서열 번호 46에 기재된 중쇄 아미노산 서열 및 서열 번호 48에 기재된 경쇄 아미노산 서열을 포함하는 항체;w) 시그널 서열 없이, 서열 번호 50에 기재된 중쇄 아미노산 서열 및 서열 번호 52에 기재된 경쇄 아미노산 서열을 포함하는 항체;x) 시그널 서열 없이, 서열 번호 66에 기재된 중쇄 아미노산 서열 및 서열 번호 52에 기재된 경쇄 아미노산 서열을 포함하는 항체;y) 시그널 서열 없이, 서열 번호 70에 기재된 중쇄 아미노산 서열 및 서열 번호 52에 기재된 경쇄 아미노산 서열을 포함하는 항체; 및z) 시그널 서열 없이, 서열 번호 86에 기재된 중쇄 아미노산 서열 및 서열 번호 48에 기재된 경쇄 아미노산 서열을 포함하는 항체로 구성되는 군으로부터 선택되는, M-CSF에 특이적으로 결합하는 모노클로날 항체.
- 제1항에 있어서,a) 모노클로날 항체 252, 88, 100, 3.8.3, 2.7.3, 1.120.1, 9.14.4I, 8.10.3F, 9.7.2IF, 9.14.4, 8.10.3, 9.7.2, 9.7.2C-Ser, 9.14.4C-Ser, 8.10.3C-Ser, 8.10.3-CG2, 9.7.2-CG2, 9.7.2-CG4, 9.14.4-CG2, 9.14.4-CG4, 9.14.4-Ser, 9.7.2-Ser, 8.10.3-Ser, 8.10.3-CG4, 8.10.3FG1 및 9.14.4G1로 구성되는 군으로부터 선택되는 항체의 중쇄로부터 독립적으로 선택되는 중쇄 CDR1, CDR2, 및 CDR3; 또는b) 모노클로날 항체 252, 88, 100, 3.8.3, 2.7.3, 1.120.1, 9.14.4I, 8.10.3F, 9.7.2IF, 9.14.4, 8.10.3, 9.7.2, 9.7.2C-Ser, 9.14.4C-Ser, 8.10.3C-Ser, 8.10.3-CG2, 9.7.2-CG2, 9.7.2-CG4, 9.14.4-CG2, 9.14.4-CG4, 9.14.4-Ser, 9.7.2-Ser, 8.10.3-Ser, 8.10.3-CG4, 8.10.3FG1 및 9.14.4G1로 구성되는 군으로부터 선택되는 항체의 경쇄로부터 독립적으로 선택되는 경쇄 CDR1, CDR2, 및 CDR3를 포함하는 인간 모노클로날 항체 또는 이의 항원-결합 부위.
- a) 중쇄가 항체 252, 88, 100, 3.8.3, 2.7.3, 1.120.1, 9.14.4I, 8.10.3F, 9.7.2IF, 9.14.4, 8.10.3, 9.7.2, 9.7.2C-Ser, 9.14.4C-Ser, 8.10.3C-Ser, 8.10.3-CG2, 9.7.2-CG2, 9.7.2-CG4, 9.14.4-CG2, 9.14.4-CG4, 9.14.4-Ser, 9.7.2-Ser, 8.10.3-Ser, 8.10.3-CG4, 8.10.3FG1 및 9.14.4G1로 구성되는 군으로부터 선택되는 항체의 중쇄 CDR1, CDR2 및 CDR3를 포함하거나;b) 경쇄가 항체 252, 88, 100, 3.8.3, 2.7.3, 1.120.1, 9.14.4I, 8.10.3F, 9.7.2IF, 9.14.4, 8.10.3, 9.7.2, 9.7.2C-Ser, 9.14.4C-Ser, 8.10.3C-Ser, 8.10.3-CG2, 9.7.2-CG2, 9.7.2-CG4, 9.14.4-CG2, 9.14.4-CG4, 9.14.4-Ser, 9.7.2-Ser, 8.10.3-Ser, 8.10.3-CG4, 8.10.3FG1 및 9.14.4G1로 구성되는 군으로부터 선택되는 항체의 중쇄 CDR1, CDR2 및 CDR3를 포함하거나;c) (a)의 중쇄 및 (b)의 경쇄를 포함하거나; 또는d) 중쇄 및 경쇄 CDR 아미노산 서열이 동일한 항체로부터 선택되는 (c)의 항체인,M-CSF에 특이적으로 결합하는 모노클로날 항체 또는 이의 항원-결합 부위.
- a) 항체 252, 88, 100, 3.8.3, 2.7.3, 1.120.1, 9.14.4I, 8.10.3F, 9.7.2IF, 9.14.4, 8.10.3, 9.7.2, 9.7.2C-Ser, 9.14.4C-Ser, 8.10.3C-Ser, 8.10.3-CG2, 9.7.2-CG2, 9.7.2-CG4, 9.14.4-CG2, 9.14.4-CG4, 9.14.4-Ser, 9.7.2-Ser, 8.10.3-Ser, 8.10.3-CG4, 8.10.3FG1 및 9.14.4G1로 구성되는 군으로부터 선택되는 항체의 중쇄의 CDR1의 첫 아미노산부터 CDR3의 마지막 아미노산까지의 아미노산 서열을 포함하는 중쇄;b) 항체 252, 88, 100, 3.8.3, 2.7.3, 1.120.1, 9.14.4I, 8.10.3F, 9.7.2IF, 9.14.4, 8.10.3, 9.7.2, 9.7.2C-Ser, 9.14.4C-Ser, 8.10.3C-Ser, 8.10.3-CG2, 9.7.2-CG2, 9.7.2-CG4, 9.14.4-CG2, 9.14.4-CG4, 9.14.4-Ser, 9.7.2-Ser, 8.10.3-Ser, 8.10.3-CG4, 8.10.3FG1 및 9.14.4G1로 구성되는 군으로부터 선택되는 항체의 경쇄의 CDR1의 첫 아미노산부터 CDR3의 마지막 아미노산까지의 아미노산 서열을 포함하는 경쇄;c) (a)의 중쇄 및 (b)의 경쇄; 또는d) 동일한 항체로부터 선택되는 아미노산 서열을 갖는 (a)의 중쇄 및 (b)의 경쇄를 포함하는 것인, M-CSF에 특이적으로 결합하는 모노클로날 항체 또는 이의 항원-결합 부위.
- 제10항에 있어서,a) 항체 252, 88, 100, 3.8.3, 2.7.3, 1.120.1, 9.14.4I, 8.10.3F, 9.7.2IF, 9.14.4, 8.10.3, 9.7.2, 9.7.2C-Ser, 9.14.4C-Ser, 8.10.3C-Ser, 8.10.3-CG2, 9.7.2-CG2, 9.7.2-CG4, 9.14.4-CG2, 9.14.4-CG4, 9.14.4-Ser, 9.7.2-Ser, 8.10.3-Ser, 8.10.3-CG4, 8.10.3FG1 및 9.14.4G1로 구성되는 군으로부터 선택되는 항체의 중쇄 가변 도메인(VH) 아미노산 서열(시그널 서열 없음);b) 항체 252, 88, 100, 3.8.3, 2.7.3, 1.120.1, 9.14.4I, 8.10.3F, 9.7.2IF, 9.14.4, 8.10.3, 9.7.2, 9.7.2C-Ser, 9.14.4C-Ser, 8.10.3C-Ser, 8.10.3-CG2, 9.7.2-CG2, 9.7.2-CG4, 9.14.4-CG2, 9.14.4-CG4, 9.14.4-Ser, 9.7.2-Ser, 8.10.3-Ser, 8.10.3-CG4, 8.10.3FG1 및 9.14.4G1로 구성되는 군으로부터 선택되는 항체의 경쇄 가변 도메인(VL) 아미노산 서열(시그널 서열 없음);c) (a)의 VH 아미노산 서열 및 (b)의 VL 아미노산 서열; 또는d) 동일 항체에서 유래하는 (a)의 VH 아미노산 서열 및 (b)의 VL 아미노산 서열을 포함하는 모노클로날 항체 또는 이의 항원-결합 부위.
- a) 시그널 서열 없이 서열 번호 2의 아미노산 서열을 포함하는 폴리펩티드;b) 시그널 서열 없이 서열 번호 6의 아미노산 서열을 포함하는 폴리펩티드;c) 시그널 서열 없이 서열 번호 10의 아미노산 서열을 포함하는 폴리펩티드;d) 시그널 서열 없이 서열 번호 14의 아미노산 서열을 포함하는 폴리펩티드;e) 시그널 서열 없이 서열 번호 18의 아미노산 서열을 포함하는 폴리펩티드;f) 시그널 서열 없이 서열 번호 22의 아미노산 서열을 포함하는 폴리펩티드;g) 시그널 서열 없이 서열 번호 26의 아미노산 서열을 포함하는 폴리펩티드;h) 시그널 서열 없이 서열 번호 30의 아미노산 서열을 포함하는 폴리펩티드;i) 시그널 서열 없이 서열 번호 34의 아미노산 서열을 포함하는 폴리펩티드;j) 시그널 서열 없이 서열 번호 38의 아미노산 서열을 포함하는 폴리펩티드;k) 시그널 서열 없이 서열 번호 46의 아미노산 서열을 포함하는 폴리펩티드;l) 시그널 서열 없이 서열 번호 50의 아미노산 서열을 포함하는 폴리펩티드;m) 시그널 서열 없이 서열 번호 54의 아미노산 서열을 포함하는 폴리펩티드;n) 시그널 서열 없이 서열 번호 58의 아미노산 서열을 포함하는 폴리펩티드;o) 시그널 서열 없이 서열 번호 62의 아미노산 서열을 포함하는 폴리펩티드;p) 시그널 서열 없이 서열 번호 66의 아미노산 서열을 포함하는 폴리펩티드;q) 시그널 서열 없이 서열 번호 70의 아미노산 서열을 포함하는 폴리펩티드;r) 시그널 서열 없이 서열 번호 74의 아미노산 서열을 포함하는 폴리펩티드;s) 시그널 서열 없이 서열 번호 78의 아미노산 서열을 포함하는 폴리펩티드;t) 시그널 서열 없이 서열 번호 82의 아미노산 서열을 포함하는 폴리펩티드;u) 시그널 서열 없이 서열 번호 86의 아미노산 서열을 포함하는 폴리펩티드;v) 시그널 서열 없이 서열 번호 90의 아미노산 서열을 포함하는 폴리펩티드;w) 시그널 서열 없이 서열 번호 94의 아미노산 서열을 포함하는 폴리펩티드;x) 시그널 서열 없이 서열 번호 98의 아미노산 서열을 포함하는 폴리펩티드;y) 시그널 서열 없이 서열 번호 102의 아미노산 서열을 포함하는 폴리펩티드로 구성되는 군으로부터 선택되는 폴리펩티드.
- 제12항에 있어서, 시그널 서열 없이 서열 번호 30의 아미노산 서열을 포함하는 폴리펩티드.
- 제12항에 있어서, 시그널 서열 없이 서열 번호 26의 아미노산 서열을 포함하는 폴리펩티드.
- a) 시그널 서열 없이 서열 번호 4의 아미노산 서열을 포함하는 폴리펩티드;b) 시그널 서열 없이 서열 번호 8의 아미노산 서열을 포함하는 폴리펩티드;c) 시그널 서열 없이 서열 번호 12의 아미노산 서열을 포함하는 폴리펩티드;d) 시그널 서열 없이 서열 번호 16의 아미노산 서열을 포함하는 폴리펩티드;e) 시그널 서열 없이 서열 번호 20의 아미노산 서열을 포함하는 폴리펩티드;f) 시그널 서열 없이 서열 번호 24의 아미노산 서열을 포함하는 폴리펩티드;g) 시그널 서열 없이 서열 번호 28의 아미노산 서열을 포함하는 폴리펩티드;h) 시그널 서열 없이 서열 번호 32의 아미노산 서열을 포함하는 폴리펩티드;i) 시그널 서열 없이 서열 번호 36의 아미노산 서열을 포함하는 폴리펩티드;j) 시그널 서열 없이 서열 번호 44의 아미노산 서열을 포함하는 폴리펩티드;k) 시그널 서열 없이 서열 번호 48의 아미노산 서열을 포함하는 폴리펩티드;l) 시그널 서열 없이 서열 번호 52의 아미노산 서열을 포함하는 폴리펩티드;m) 시그널 서열 없이 서열 번호 56의 아미노산 서열을 포함하는 폴리펩티드;n) 시그널 서열 없이 서열 번호 60의 아미노산 서열을 포함하는 폴리펩티드로 구성되는 군으로부터 선택되는 폴리펩티드.
- 제15항에 있어서, 시그널 서열 없이 서열 번호 32의 아미노산 서열을 포함하는 폴리펩티드.
- 제15항에 있어서, 시그널 서열 없이 서열 번호 28의 아미노산 서열을 포함하는 폴리펩티드.
- 항체 252, 88, 100, 3.8.3, 2.7.3, 1.120.1, 9.14.4I, 8.10.3F, 9.7.2IF, 9.14.4, 8.10.3, 9.7.2, 9.7.2C-Ser, 9.14.4C-Ser, 8.10.3C-Ser, 8.10.3-CG2, 9.7.2-CG2, 9.7.2-CG4, 9.14.4-CG2, 9.14.4-CG4, 9.14.4-Ser, 9.7.2-Ser, 8.10.3-Ser, 8.10.3-CG4, 8.10.3FG1 및 9.14.4G1로 구성되는 군으로부터 선택되는 항체의 FR1, FR2, FR3 또는 F4 아미노산 서열 중 하나 이상을 포함하는, M-CSF에 특이적으로 결합하는 모노클로날 항체 또는 이의 항원-결합 부위.
- 제1항에 있어서,a) 시그널 서열 없이, 모노클로날 항체 252, 88, 100, 3.8.3, 2.7.3, 1.120.1, 9.14.4I, 8.10.3F, 9.7.2IF, 9.14.4, 8.10.3, 9.7.2, 9.7.2C-Ser, 9.14.4C-Ser, 8.10.3C-Ser, 8.10.3-CG2, 9.7.2-CG2, 9.7.2-CG4, 9.14.4-CG2, 9.14.4-CG4, 9.14.4-Ser, 9.7.2-Ser, 8.10.3-Ser, 8.10.3-CG4, 8.10.3FG1 또는9.14.4G1의 중쇄 아미노산 서열과 90% 이상 동일한 중쇄 아미노산 서열;b) 시그널 서열 없이, 모노클로날 항체 252, 88, 100, 3.8.3, 2.7.3, 1.120.1, 9.14.4I, 8.10.3F, 9.7.2IF, 9.14.4, 8.10.3, 9.7.2, 9.7.2C-Ser, 9.14.4C-Ser, 8.10.3C-Ser, 8.10.3-CG2, 9.7.2-CG2, 9.7.2-CG4, 9.14.4-CG2, 9.14.4-CG4, 9.14.4-Ser, 9.7.2-Ser, 8.10.3-Ser, 8.10.3-CG4, 8.10.3FG1 또는 9.14.4G1의 경쇄 아미노산 서열과 90% 이상 동일한 경쇄 아미노산 서열; 또는c) (a)의 중쇄 아미노산 서열 및 (b)의 경쇄 아미노산 서열을 포함하는 인간 모노클로날 항체.
- 제1항 내지 제19항 중 어느 한 항에 있어서, 상기 항체 또는 항원-결합 부위의 중쇄의 C-말단 리신이 존재하지 않는 모노클로날 항체 또는 이의 항원-결합 부위.
- 제1항 내지 제20항 중 어느 한 항의 항체 또는 이의 항원-결합 부위 및 약학적으로 허용가능한 담체를 포함하는 약학 조성물.
- 제21항에 있어서, 항체가 모노클로날 항-M-CSF 항체 9.14.4I 또는 8.10.3F인 약학 조성물.
- M-CSF를 억제하는 제1항 내지 제 20항 중 어느 한 항에 따른 항체 또는 이의 항원-결합 부위, 또는 제21항 또는 제22항의 약학 조성물의 치료 유효량을 치료가 필요한 대상체에게 투여하는 단계를 포함하는, 인간을 비롯한 대상체에서 관절염, 건선 관절염, 강직척추염, 라이터 증후군, 류마티스성 관절염, 통풍, 외상성 관절염, 풍진 관절염 및 급성 윤활막염 및 기타 관절염 증상, 패혈증, 패혈성 쇼크, 내독소 쇼크, 그람 음성 패혈증, 독성 쇼크 증후군, 알츠하이머 병, 졸중, 신경외상, 천식, 성인 호흡 곤란 증후군, 뇌 말라리아, 만성 폐렴 염증 질병, 규소폐증, 폐사르코이드증, 뼈 흡수 질병, 골다공증, 재협착, 심장 및 신장 재관류 손상, 혈전증, 사구체신염, 당뇨병, 이식편 대 숙주 반응, 동종이식 거부, 염증성 장 질병, 크론 병, 궤양성 결장염, 다발성 경화증, 근육 퇴화, 습진, 접촉성 피부염, 건선, 일광화상, 및 결막염 쇼크로 구성되는 군으로부터 선택되는 증상을 치료하는 방법.
- 제23항에 있어서, 상기 증상이 류마티스성 관절염인 방법.
- 제23항 또는 제24항에 있어서, 사용되는 항체가 모노클로날 항-M-CSF 항체 8.10.3F 또는 9.14.4I인 방법.
- c- fms에의 M-CSF 결합을 억제하는 제1항 내지 제 20항 중 어느 한 항에 따른 항체 또는 이의 항원-결합 부위 또는 제21항 또는 제22항의 약학 조성물을 대상체 에게 투여하는 단계를 포함하는, 인간을 비롯한 대상체에서 육종, 암종과 같은 고형 종양 또는 림프종과 같은 비-고형 종양을 치료하는 방법.
- 제1항 내지 제20항 중 어느 한 항의 항체 또는 이의 항원-결합 부위 또는 상기 항체 또는 상기 항원-결합 부위의 중쇄 또는 경쇄를 생산하는 단리된 세포주.
- 제27항에 있어서, 항체 252, 88, 100, 3.8.3, 2.7.3, 1.120.1, 9.14.4I, 8.10.3F, 9.7.2IF, 9.14.4, 8.10.3, 9.7.2, 9.7.2C-Ser, 9.14.4C-Ser, 8.10.3C-Ser, 8.10.3-CG2, 9.7.2-CG2, 9.7.2-CG4, 9.14.4-CG2, 9.14.4-CG4, 9.14.4-Ser, 9.7.2-Ser, 8.10.3-Ser, 8.10.3-CG4, 8.10.3FG1 및 9.14.4G1으로 구성되는 군으로부터 선택되는 항체 및 전술한 항체 중 하나와 동일한 아미노산 서열을 갖는 항체를 생산하는 세포주.
- 제1항 내지 제20항 중 어느 한 항에 따른 항체의 중쇄 또는 이의 항원-결합 부위 또는 경쇄 또는 이의 항원-결합 부위를 암호하는 뉴클레오티드 서열을 포함하는 단리된 핵산 분자.
- 제29항의 핵산 분자 및 임의로 이 핵산 분자에 작동가능하게 연결된 발현 조절 서열을 포함하는 벡터.
- 제30항의 벡터 또는 제29항의 핵산 분자를 포함하는 숙주 세포.
- 제31항에 있어서, 제1항 내지 제20항 중 어느 한 항의 항체 또는 이의 항원-결합 부위의 중쇄를 암호하는 핵산 분자 및 경쇄를 암호하는 핵산 분자를 포함하는 숙주 세포.
- 적합한 조건하에서 제32항의 숙주 세포 또는 제28항의 세포주를 배양하고 항-M-CSF 항체 또는 이의 항원-결합 부위를 회수하는 것을 포함하는, 항-M-CSF 항체 또는 이의 항원-결합 부위의 제조 방법.
- a) 인간 항체를 생산할 수 있는 비-인간 형질전환 동물을 M-CSF, M-CSF의 면역원성 부위 또는 M-CSF를 발현하는 세포 또는 조직으로 면역화시키는 단계;b) 상기 형질전환 동물이 M-CSF에 대한 면역반응을 일으키게 하는 단계; 및c) 상기 형질전환 동물로부터 B 림프구를 단리하는 단계를 포함하는, M-CSF에 특이적으로 결합하는 인간 모노클로날 항체의 제조 방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50216303P | 2003-09-10 | 2003-09-10 | |
US60/502,163 | 2003-09-10 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067006880A Division KR100899213B1 (ko) | 2003-09-10 | 2004-09-09 | M-csf에 대한 항체 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080068146A true KR20080068146A (ko) | 2008-07-22 |
KR100938452B1 KR100938452B1 (ko) | 2010-01-25 |
Family
ID=33300142
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067006880A KR100899213B1 (ko) | 2003-09-10 | 2004-09-09 | M-csf에 대한 항체 |
KR1020087015841A KR100938452B1 (ko) | 2003-09-10 | 2004-09-09 | M-csf에 대한 항체 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067006880A KR100899213B1 (ko) | 2003-09-10 | 2004-09-09 | M-csf에 대한 항체 |
Country Status (42)
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110091451A1 (en) * | 2002-11-15 | 2011-04-21 | Kavanaugh William M | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
GB0325836D0 (en) * | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
PT2311873T (pt) | 2004-01-07 | 2018-11-20 | Novartis Vaccines & Diagnostics Inc | Anticorpo monoclonal específico para m-csf e respetivos usos |
CA2590671A1 (en) * | 2004-11-18 | 2006-05-26 | Imclone Systems Incorporated | Antibodies against vascular endothelial growth factor receptor-1 |
BRPI0608855A2 (pt) * | 2005-03-08 | 2010-02-02 | Pharmacia & Upjohn Co Llc | composições de anticorpo anti - madcam processo para a preparação das mesmas e uso de anticorpo anti - madcam |
EP1858928A2 (en) * | 2005-03-08 | 2007-11-28 | Pharmacia & Upjohn Company LLC | Anti-m-csf antibody compositions having reduced levels of endotoxin |
EP1913028B1 (en) * | 2005-07-28 | 2015-03-04 | Novartis AG | Use of antibody to m-csf |
JP5457671B2 (ja) * | 2005-07-28 | 2014-04-02 | ノバルティス アーゲー | M−csf特異的モノクローナル抗体およびその使用 |
JP4736037B2 (ja) * | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
TWI390034B (zh) * | 2006-04-06 | 2013-03-21 | Kyowa Hakko Kirin Co Ltd | Novel anti-CD98 antibody |
CL2007002225A1 (es) * | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
AU2008214476A1 (en) * | 2007-02-06 | 2008-08-14 | Ribovax Biotechnologies S.A. | Antibodies specific for varicella zoster virus |
EP3330292A1 (en) | 2007-08-21 | 2018-06-06 | Amgen, Inc | Human c-fms antigen binding proteins |
US20090104148A1 (en) * | 2007-09-18 | 2009-04-23 | Jay Gregory D | Treatment and prevention of joint disease |
CA2700860C (en) | 2007-10-01 | 2016-07-19 | Jonathan A. Terrett | Human antibodies that bind mesothelin, and uses thereof |
EP2215482A2 (en) * | 2007-10-31 | 2010-08-11 | Janssen Pharmaceutica N.V. | Biomarker for assessing response to fms treatment |
CA2705539A1 (en) * | 2007-11-13 | 2009-05-22 | Evec Inc. | Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same |
RU2509777C2 (ru) * | 2008-01-04 | 2014-03-20 | Бакстер Интернэшнл Инк. | Анти-mif антитела |
CN102702358B (zh) * | 2008-03-14 | 2016-02-17 | 天士力创世杰(天津)生物制药有限公司 | 针对csf-1r的抗体 |
US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
JP2010043063A (ja) * | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | 川崎病の診断及び治療 |
AU2010222930B2 (en) | 2008-07-16 | 2013-07-25 | Baylor Research Institute | Antigen presenting cell targeted cancer vaccines |
CA3032548C (en) | 2009-03-10 | 2023-05-09 | Baylor Research Institute | Anti-cd40 antibodies and uses thereof |
JP2012521197A (ja) | 2009-03-20 | 2012-09-13 | アムジエン・インコーポレーテツド | 担体免疫グロブリンおよびその使用 |
CU23736A1 (es) | 2009-05-04 | 2011-11-15 | Centro Inmunologia Molecular | Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso |
US8877199B2 (en) | 2009-05-15 | 2014-11-04 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | B cell surface reactive antibodies |
WO2011023785A1 (en) * | 2009-08-27 | 2011-03-03 | Novo Nordisk A/S | Targeting tissue factor to activated platelets |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
US20120208208A1 (en) * | 2009-10-30 | 2012-08-16 | Ni Yan G | Pcsk9 immunoassay |
SI2566517T1 (sl) * | 2010-05-04 | 2019-01-31 | Five Prime Therapeutics, Inc. | Protitelesa, ki vežejo CSF1R |
PT2569013T (pt) * | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
SG186421A1 (en) | 2010-07-02 | 2013-01-30 | Medimmune Llc | Antibody formulations |
US8993727B2 (en) | 2010-09-22 | 2015-03-31 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
AU2015234335B2 (en) * | 2010-09-29 | 2017-09-28 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins |
KR20130130709A (ko) | 2010-09-29 | 2013-12-02 | 어젠시스 인코포레이티드 | 191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(adc) |
CN102603649B (zh) * | 2011-01-20 | 2016-05-25 | 赣南师范学院 | 一种以地巴唑为先导分子的荧光探针化合物及其制备方法 |
EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
JP2014520873A (ja) | 2011-07-18 | 2014-08-25 | ザ ユニバーシティ オブ メルボルン | c−Fmsアンタゴニストの使用 |
CN104271599A (zh) * | 2011-11-08 | 2015-01-07 | 辉瑞公司 | 使用抗m-csf抗体治疗炎性疾病的方法 |
US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
UY34813A (es) | 2012-05-18 | 2013-11-29 | Amgen Inc | Proteínas de unión a antígeno dirigidas contra el receptor st2 |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
KR20150140752A (ko) | 2013-04-12 | 2015-12-16 | 모르포시스 아게 | M-csf를 표적으로 하는 항체 |
GB201315487D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
EP3041863A4 (en) | 2013-09-05 | 2017-08-16 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
EP3080161B1 (en) | 2013-12-09 | 2021-03-24 | New York University | Compositions and methods for phagocyte delivery of anti-staphylococcal agents |
US10286058B2 (en) | 2014-01-13 | 2019-05-14 | Baylor Research Institute | Vaccines against HPV and HPV-related diseases |
MX2016014761A (es) | 2014-05-16 | 2017-05-25 | Amgen Inc | Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2). |
WO2015200089A1 (en) | 2014-06-23 | 2015-12-30 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
WO2016120828A1 (en) | 2015-01-30 | 2016-08-04 | Novartis Ag | Treatment of breast cancer by m-csf antagonist |
AU2016222928B2 (en) | 2015-02-26 | 2021-05-13 | Merck Patent Gmbh | PD-1 / PD-L1 inhibitors for the treatment of cancer |
EP3310810A1 (en) | 2015-06-16 | 2018-04-25 | Merck Patent GmbH | Pd-l1 antagonist combination treatments |
BR112018068340A2 (pt) | 2016-03-11 | 2019-01-15 | Scholar Rock Inc | imunoglobulinas de ligação ao tgfss1 e usos destas |
CN109843324A (zh) | 2016-10-06 | 2019-06-04 | 辉瑞公司 | 用于治疗癌症的avelumab用药方案 |
CN110382530A (zh) * | 2017-01-06 | 2019-10-25 | 供石公司 | 亚型特异性、背景许可性TGFβ1抑制剂及其用途 |
SG11201908328XA (en) | 2017-03-14 | 2019-10-30 | Amgen Inc | Control of total afucosylated glycoforms of antibodies produced in cell culture |
US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
EP4116327A1 (en) | 2017-10-11 | 2023-01-11 | Board Of Regents, The University Of Texas System | Human pd-l1 antibodies and methods of use therefor |
WO2019136241A1 (en) * | 2018-01-05 | 2019-07-11 | Modernatx, Inc. | Polynucleotides encoding anti-chikungunya virus antibodies |
SG11202007518RA (en) | 2018-02-28 | 2020-09-29 | Pfizer | Il-15 variants and uses thereof |
US20210214445A1 (en) * | 2018-03-23 | 2021-07-15 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor |
CA3093853A1 (en) | 2018-03-26 | 2019-10-03 | Amgen Inc. | Total afucosylated glycoforms of antibodies produced in cell culture |
KR102602329B1 (ko) | 2018-05-23 | 2023-11-16 | 화이자 인코포레이티드 | Cd3에 특이적인 항체 및 이의 용도 |
WO2019224716A2 (en) | 2018-05-23 | 2019-11-28 | Pfizer Inc. | Antibodies specific for gucy2c and uses thereof |
JP2021531245A (ja) | 2018-07-10 | 2021-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 既存の相互作用を最小化する改変結合分子 |
WO2020044252A1 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Dosage regimes for anti-m-csf antibodies and uses thereof |
WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
US11339159B2 (en) | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
US20220349898A1 (en) | 2019-09-26 | 2022-11-03 | Amgen Inc. | Methods of producing antibody compositions |
AU2020410410A1 (en) | 2019-12-17 | 2022-06-09 | Pfizer Inc. | Antibodies specific for CD47, PD-L1, and uses thereof |
CA3164804A1 (en) | 2019-12-18 | 2021-06-24 | Pfizer Inc. | Once daily cancer treatment regimen with a prmt5 inhibitor |
JP2021134154A (ja) * | 2020-02-25 | 2021-09-13 | シスメックス株式会社 | 改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法 |
WO2021181233A2 (en) | 2020-03-09 | 2021-09-16 | Pfizer Inc. | Fusion proteins and uses thereof |
US20230192878A1 (en) | 2020-05-13 | 2023-06-22 | Pfizer Inc. | Methods, therapies and uses for treating cancer |
US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
CN116323668A (zh) | 2020-07-17 | 2023-06-23 | 辉瑞公司 | 治疗性抗体及其用途 |
KR20230069181A (ko) | 2020-09-14 | 2023-05-18 | 화이자 인코포레이티드 | 암 치료를 위한 방법, 요법 및 용도 |
US20240043501A1 (en) | 2020-10-15 | 2024-02-08 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
WO2022153161A1 (en) | 2021-01-14 | 2022-07-21 | Pfizer Inc. | Treatment of cancer using a prmt5 inhibitor |
AU2022227029A1 (en) * | 2021-02-26 | 2023-08-31 | New York University | Compositions and methods comprising antibodies that bind to covalent peptide conjugates |
TW202317614A (zh) | 2021-06-07 | 2023-05-01 | 美商安進公司 | 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平 |
CA3233279A1 (en) | 2021-10-05 | 2023-04-13 | Amgen, Inc. | Fc-gamma receptor ii binding and glycan content |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
WO2023218320A1 (en) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Anti-lymphotoxin beta receptor antibodies and methods of use thereof |
WO2023242769A1 (en) | 2022-06-17 | 2023-12-21 | Pfizer Inc. | Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof |
WO2024003773A1 (en) | 2022-07-01 | 2024-01-04 | Pfizer Inc. | 2,7-naphthyridine compounds as mastl inhibitors |
WO2024009191A1 (en) | 2022-07-05 | 2024-01-11 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
WO2024074977A1 (en) | 2022-10-04 | 2024-04-11 | Pfizer Inc. | Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds |
Family Cites Families (244)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5531159A (en) | 1978-08-26 | 1980-03-05 | Sumitomo Metal Ind Ltd | Manufacture of high strength cold rolled steel plate for press working |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4504586A (en) * | 1983-02-03 | 1985-03-12 | Amgen | Hybridoma tumor cell lines and their monoclonal antibodies to human colony stimulating factor subclass number 1 |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5573930A (en) | 1985-02-05 | 1996-11-12 | Cetus Oncology Corporation | DNA encoding various forms of colony stimulating factor-1 |
US4847201A (en) | 1985-02-05 | 1989-07-11 | Cetus Corporation | DNA encoding for CSF-1 and accompanying recombinant systems |
US6103224A (en) | 1985-02-05 | 2000-08-15 | Chiron Corporation | N∇2 CSF-1 (short form) and carboxy truncated fragments thereof |
WO1986004607A1 (en) | 1985-02-05 | 1986-08-14 | Cetus Corporation | Recombinant colony stimulating factor-1 |
US5792450A (en) | 1985-02-05 | 1998-08-11 | Chiron Corporation | Purified human CSF-1 |
US5837229A (en) | 1985-02-05 | 1998-11-17 | Chiron Corporation | Uses of recombinant colony stimulating factor-1 |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
HU212277B (en) | 1986-05-06 | 1996-04-29 | Genetics Inst | Process for producing m-csf |
US4868119A (en) | 1986-12-11 | 1989-09-19 | Genetics Institute, Inc. | Hematopoietic growth factors |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
GB8624899D0 (en) | 1986-10-17 | 1986-11-19 | Sandoz Ltd | Monoclonal antibodies |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US4929700A (en) | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
CA1339757C (en) | 1987-04-16 | 1998-03-17 | Robert F. Halenbeck | Production of purified biologically active, bacterially produced recombinant human csf-1 |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US4929455A (en) * | 1988-07-07 | 1990-05-29 | Mallinckrodt, Inc. | Flour-based pot pie crusts with improved texture |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
EP0457804B1 (en) * | 1989-02-10 | 1996-08-14 | Cetus Oncology Corporation | M-csf monoclonal antibodies that recognize a neutralizing conformational epitope |
MY105946A (en) | 1989-07-14 | 1995-02-28 | Schering Corp | Antagonists of gm-csf derived from the carboxyl terminus. |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
JPH05503098A (ja) * | 1989-12-15 | 1993-05-27 | カイロン コーポレイション | セプシスの処理のためのサイトカイン抗体 |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JP3068180B2 (ja) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | 異種抗体の生成 |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
ATE185601T1 (de) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
JPH06506105A (ja) | 1990-08-29 | 1994-07-14 | ファーミング ビーブイ | 哺乳動物細胞における相同性組換え |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
CA2060741A1 (en) | 1991-02-11 | 1992-08-12 | Robert S. Greenfield | Gm-csf inhibiting oligopeptides |
EP0575485A1 (en) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Process for the development of binding mini-proteins |
IE921169A1 (en) | 1991-04-10 | 1992-10-21 | Scripps Research Inst | Heterodimeric receptor libraries using phagemids |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Tech | Methoden zur Herstellung humanisierter Antikörper |
JPH0595794A (ja) * | 1991-10-04 | 1993-04-20 | Otsuka Pharmaceut Co Ltd | ヒトm−csf抗体及びヒトm−csfの測定法 |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP0618970A1 (en) | 1991-12-10 | 1994-10-12 | Dana Farber Cancer Institute | Reactive neutralizing human anti-gp120 recombinant antibody, dna coding the same and use thereof |
JPH067189A (ja) | 1991-12-17 | 1994-01-18 | Morinaga Milk Ind Co Ltd | ヒトM−CSF β型ダイマ−に特異性を有するモノクロ− ナル抗体と、この抗体を産生するハイブリドーマ、お よびこの抗体の利用 |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
DE69329247T2 (de) | 1992-06-09 | 2001-05-31 | Chiron Corp | Kristallisierung von m-csf |
ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
JP3714683B2 (ja) | 1992-07-30 | 2005-11-09 | 生化学工業株式会社 | 抗リウマチ剤 |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
JPH06194367A (ja) | 1992-12-25 | 1994-07-15 | Morinaga Milk Ind Co Ltd | リウマチ疾患の診断方法 |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
EP0804070B1 (en) | 1993-03-09 | 2000-05-24 | Genzyme Corporation | Process of isolation of proteins from milk |
JPH06319584A (ja) | 1993-05-07 | 1994-11-22 | Morinaga Milk Ind Co Ltd | 抗m−csfモノクロ−ナル抗体と、この抗体を産生 するハイブリド−マ |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
WO1995029690A1 (en) | 1994-04-29 | 1995-11-09 | The Trustees Of The University Of Pennsylvania | Biologically active peptides and methods of identifying the same |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
KR100479146B1 (ko) | 1995-04-21 | 2005-05-16 | 셀 제네시스, 인코포레이티드 | 큰게놈dna결실유발법 |
CA2761116A1 (en) | 1995-04-27 | 1996-10-31 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
BR9710362A (pt) | 1996-07-13 | 1999-08-17 | Glaxo Group Ltd | Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto |
DE69716916T2 (de) | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
DE69712496T2 (de) | 1996-07-18 | 2002-08-29 | Pfizer | Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren |
KR20000068248A (ko) | 1996-08-23 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 아릴설포닐아미노 하이드록삼산 유도체 |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6255455B1 (en) | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
KR20080059467A (ko) * | 1996-12-03 | 2008-06-27 | 아브게닉스, 인크. | 복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체 |
PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
US6303636B1 (en) | 1997-02-03 | 2001-10-16 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
AU5493598A (en) | 1997-02-07 | 1998-08-26 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
DE69828154T2 (de) | 1997-03-12 | 2005-06-23 | Smithkline Beecham Corp. | Anti-alphavbeta3 humanizierte monoklonale antikörper |
JP3523650B2 (ja) * | 1997-04-15 | 2004-04-26 | 三共株式会社 | 新規蛋白質及びその製造方法 |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
WO1998050356A1 (en) | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
GB2339430A (en) | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
EP0984692A4 (en) | 1997-05-30 | 2001-02-21 | Merck & Co Inc | ANGIOGENESIS INHIBITORS |
CA2299355C (en) | 1997-08-08 | 2005-09-27 | Pfizer Products Inc. | Aryloxyarylsulfonylamino hydroxamic acid derivatives |
DE69838172T2 (de) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
JP2001518470A (ja) | 1997-09-26 | 2001-10-16 | メルク エンド カムパニー インコーポレーテッド | 新規な血管形成阻害剤 |
JP2001522853A (ja) | 1997-11-11 | 2001-11-20 | ファイザー・プロダクツ・インク | 抗癌剤として有用なチエノピリミジンおよびチエノピリジン誘導体 |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
EP1060193A2 (en) | 1998-03-03 | 2000-12-20 | Abgenix, Inc. | Cd147 binding molecules as therapeutics |
JP4462654B2 (ja) | 1998-03-26 | 2010-05-12 | ソニー株式会社 | 映像素材選択装置及び映像素材選択方法 |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
WO1999061422A1 (en) | 1998-05-29 | 1999-12-02 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
AUPP525198A0 (en) | 1998-08-13 | 1998-09-03 | Medvet Science Pty. Ltd. | Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
EP1004578B1 (en) | 1998-11-05 | 2004-02-25 | Pfizer Products Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
JP2002534959A (ja) | 1998-12-08 | 2002-10-22 | バイオベーション リミテッド | 免疫原性タンパク質の改変方法 |
WO2000035956A1 (fr) * | 1998-12-16 | 2000-06-22 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps monoclonal anti-vegf humain |
OA11917A (en) | 1998-12-23 | 2006-04-13 | Abgenix Inc | Human monoclonal antibodies to ctla-4. |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
US6471429B1 (en) * | 1999-01-29 | 2002-10-29 | Canon Kabushiki Kaisha | Sheet processing apparatus for discharging sheets in a bundle |
AU5761900A (en) | 1999-06-30 | 2001-01-31 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Human monoclonal antibodies to hiv-1 envelope glycoprotein gp120 |
CA2589418A1 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
US7135287B1 (en) | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
AU1759501A (en) | 1999-11-08 | 2001-06-06 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Method of treating a viral infection using antagonists of macrophage colony stimulating factor |
US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
US6680209B1 (en) | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
US20030232054A1 (en) | 2000-01-25 | 2003-12-18 | Tang Y. Tom | Novel nucleic acids and polypeptides |
EP1285084A1 (en) | 2000-01-25 | 2003-02-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
CA2409267C (en) | 2000-05-26 | 2017-02-28 | Immunex Corporation | Interleukin-4 antagonists and compositions thereof |
KR20120053525A (ko) | 2000-06-16 | 2012-05-25 | 캠브리지 안티바디 테크놀로지 리미티드 | 면역특이적으로 BLyS에 결합하는 항체 |
US7879328B2 (en) * | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
WO2002059340A1 (en) | 2001-01-26 | 2002-08-01 | The Scripps Research Institute | Immunopolypeptides to hepatitis c virus |
NZ527977A (en) | 2001-02-12 | 2005-10-28 | Medarex Inc | Human monoclonal antibodies to FC alpha receptor (CD89) |
US20020146753A1 (en) | 2001-04-06 | 2002-10-10 | Henrik Ditzel | Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease |
CA2658221C (en) | 2001-04-27 | 2012-11-27 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
JP4025881B2 (ja) | 2001-04-27 | 2007-12-26 | キリンファーマ株式会社 | 抗cd40モノクローナル抗体 |
CA2447602C (en) | 2001-05-18 | 2011-11-01 | Kirin Beer Kabushiki Kaisha | Anti-trail-r antibodies |
FI112501B (fi) | 2001-05-18 | 2003-12-15 | Valtion Teknillinen | Heveiiniä sitovat monoklonaaliset vasta-aineet |
JP2005168497A (ja) | 2001-05-18 | 2005-06-30 | Kirin Brewery Co Ltd | 抗trail−r抗体およびその用途 |
CA2451074C (en) | 2001-06-18 | 2014-02-11 | Rosetta Inpharmatics, Inc. | Diagnosis and prognosis of breast cancer patients |
US7171311B2 (en) | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
JP4190005B2 (ja) | 2001-08-22 | 2008-12-03 | 株式会社抗体研究所 | 結合性分子の選択方法 |
WO2003033538A1 (fr) | 2001-10-15 | 2003-04-24 | Kirin Beer Kabushiki Kaisha | Anticorps anti-hlr-dr |
JP3729841B2 (ja) | 2001-10-15 | 2005-12-21 | 麒麟麦酒株式会社 | 抗hla−dr抗体の利用 |
AU2002364954A1 (en) | 2001-11-16 | 2003-07-15 | Human Genome Sciences, Inc. | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS |
CA2467738A1 (en) | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Antibodies against carboxic anhydrase ix (ca ix) tumor antigen |
CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
EP1322146A1 (en) | 2001-12-18 | 2003-06-25 | Phoenix Precision Technology Corporation | Method of electroplating solder bumps on an organic circuit board |
NZ534174A (en) | 2002-01-09 | 2007-03-30 | Medarex Inc | An isolated human monoclonal antibody which binds to human CD30 |
EP1485075A4 (en) | 2002-02-20 | 2006-04-26 | Dyax Corp | MHC-PEPTIDE COMPLEX BINDING LIGANDS |
JP2005520523A (ja) | 2002-03-21 | 2005-07-14 | イーライ・リリー・アンド・カンパニー | アンタゴニスト的抗hFasリガントヒト抗体およびそのフラグメント |
CN1886512B (zh) | 2002-04-23 | 2015-11-25 | 斯克里普斯研究所 | 多肽在叶绿体中的表达以及用于表达多肽的组合物和方法 |
US8586538B2 (en) | 2002-04-29 | 2013-11-19 | Stichting Sanquin Bloedvoorziening | Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII |
AU2003272511A1 (en) | 2002-09-13 | 2004-04-30 | Dyax Corporation | Cd44-binding ligands |
TWI320716B (en) | 2002-10-14 | 2010-02-21 | Abbott Lab | Erythropoietin receptor binding antibodies |
US7396913B2 (en) | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
EP1572106B1 (en) * | 2002-11-15 | 2010-05-05 | Novartis Vaccines and Diagnostics, Inc. | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
UA90082C2 (ru) | 2002-11-15 | 2010-04-12 | Дженмаб А/С | Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25 |
AR042145A1 (es) | 2002-11-27 | 2005-06-08 | Dow Agrociences Llc | Produccion de inmunoglobulinas en plantas con una fucocilacion reducida |
AU2003299581A1 (en) | 2002-12-02 | 2004-06-23 | Abgenix, Inc. | Antibodies against drugs of abuse |
MXPA05005925A (es) * | 2002-12-02 | 2006-02-08 | Abgenix Inc | Anticuerpos dirigidos a la fosfolipasa a2 y sus usos. |
WO2005035732A2 (en) | 2003-02-19 | 2005-04-21 | Dyax Corporation | Papp-a ligands |
CA2519528C (en) | 2003-03-19 | 2016-01-26 | Abgenix, Inc. | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
EP1625162A2 (en) | 2003-05-06 | 2006-02-15 | Albert Einstein College Of Medicine Of Yeshiva University | Compositions and methods for treatment of cryptococcosis |
US20090005257A1 (en) | 2003-05-14 | 2009-01-01 | Jespers Laurent S | Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire |
US7456264B2 (en) | 2003-05-21 | 2008-11-25 | Medarex, Inc. | Human monoclonal antibodies against Bacillus anthracis protective antigen |
WO2004108078A2 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals Inc. | Rationally designed antibodies |
GEP20104887B (en) | 2003-07-15 | 2010-02-10 | Medarex Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
EP1648510B1 (en) | 2003-07-22 | 2013-06-19 | Bayer Pharma Aktiengesellschaft | Rg1 antibodies and uses thereof |
HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
CA2535171A1 (en) | 2003-08-12 | 2005-03-03 | Dyax Corp. | Tie1-binding ligands |
AU2004266246A1 (en) | 2003-08-14 | 2005-03-03 | Dyax Corp. | Endotheliase-2 ligands |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
WO2005034733A2 (en) | 2003-10-08 | 2005-04-21 | North Shore-Long Island Jewish Research Institute | Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
WO2005047325A2 (en) | 2003-11-07 | 2005-05-26 | Amgen Inc. | Monkey immunoglobulin sequences |
US7638606B2 (en) | 2003-11-07 | 2009-12-29 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
JP4870348B2 (ja) | 2003-12-04 | 2012-02-08 | 株式会社ペルセウスプロテオミクス | 細胞表面抗原に対する抗体取得とその抗原同定 |
US7741449B2 (en) | 2003-12-10 | 2010-06-22 | Medarex, Inc. | Anti-interferon alpha antibodies |
CN102838675B (zh) | 2003-12-10 | 2014-07-30 | 梅达雷克斯有限责任公司 | Ip-10抗体及其用途 |
WO2005063819A2 (en) | 2003-12-23 | 2005-07-14 | Crucell Holland B.V. | Human binding molecule against cd1a |
PT2311873T (pt) | 2004-01-07 | 2018-11-20 | Novartis Vaccines & Diagnostics Inc | Anticorpo monoclonal específico para m-csf e respetivos usos |
PT2857418T (pt) | 2004-02-06 | 2017-10-20 | Univ Massachusetts | Anticorpos contra toxinas de clostridium difficile e utilizações dos mesmos |
US7271245B2 (en) | 2004-02-13 | 2007-09-18 | The Scripps Research Institute | Methods and compositions for inhibition of metastasis |
WO2005086713A2 (en) | 2004-03-04 | 2005-09-22 | Kirin Brewery Co., Ltd. | Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis |
AU2005227313A1 (en) | 2004-03-19 | 2005-10-06 | Amgen Inc. | Reducing the risk of human and anti-human antibodies through V gene manipulation |
CA2561533C (en) * | 2004-04-13 | 2015-06-16 | Yvo Graus | Anti-p-selectin antibodies |
WO2005109266A1 (en) | 2004-05-07 | 2005-11-17 | Snap-On Incorporated | Tool monitoring system |
ES2563491T3 (es) | 2004-07-06 | 2016-03-15 | Bioren, LLC | Bibliotecas universales de anticuerpos |
WO2006020258A2 (en) | 2004-07-17 | 2006-02-23 | Imclone Systems Incorporated | Novel tetravalent bispecific antibody |
MX2007000644A (es) | 2004-07-20 | 2007-03-28 | Symphogen As | Anticuerpo policlonal recombinante anti-rhesus d y metodos de fabricacion. |
EP1807451A2 (en) | 2004-08-03 | 2007-07-18 | Dyax Corporation | Hk1-binding proteins |
WO2006017759A2 (en) | 2004-08-05 | 2006-02-16 | Kirin Brewery Co., Ltd. | Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
JP2008532476A (ja) | 2004-08-12 | 2008-08-21 | ダイアックス コーポレーション | 複合結合タンパク質 |
CA2578361A1 (en) | 2004-08-23 | 2006-03-02 | Genesto A/S | Binding member towards pneumolysin |
CA2580981C (en) | 2004-09-22 | 2013-10-22 | Kirin Beer Kabushiki Kaisha | Stabilized human igg4 antibodies |
KR20070083899A (ko) | 2004-10-01 | 2007-08-24 | 메다렉스, 인코포레이티드 | Cd30 양성 림프종의 치료 방법 |
KR100619546B1 (ko) | 2004-10-05 | 2006-09-04 | 아주대학교산학협력단 | 히스톤 h2a 및/또는 h2b에 대한 인간 모노클로날자가항체 및 그 단편 |
CA2590671A1 (en) | 2004-11-18 | 2006-05-26 | Imclone Systems Incorporated | Antibodies against vascular endothelial growth factor receptor-1 |
DE602005022928D1 (de) | 2004-11-30 | 2010-09-23 | Abgenix Inc | Antikörper gegen gpnmb und ihre verwendungen |
AU2005319382B2 (en) * | 2004-12-21 | 2011-04-07 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
TWI306862B (en) | 2005-01-03 | 2009-03-01 | Hoffmann La Roche | Antibodies against il-13 receptor alpha 1 and uses thereof |
EP1851245B1 (en) | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
EP1848745B1 (en) | 2005-02-18 | 2014-07-09 | Medarex, L.L.C. | Monoclonal antibodies against cd30 lacking in fucosyl residues |
BRPI0608855A2 (pt) | 2005-03-08 | 2010-02-02 | Pharmacia & Upjohn Co Llc | composições de anticorpo anti - madcam processo para a preparação das mesmas e uso de anticorpo anti - madcam |
EP1858928A2 (en) | 2005-03-08 | 2007-11-28 | Pharmacia & Upjohn Company LLC | Anti-m-csf antibody compositions having reduced levels of endotoxin |
WO2006137931A2 (en) | 2005-03-14 | 2006-12-28 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Serivces | Human monoclonal antibodies against hendra and nipah viruses |
CA2602663A1 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc variants with optimized properties |
EP1874820A4 (en) | 2005-04-20 | 2010-09-22 | Amgen Fremont Inc | HIGH AFFINE, COMPLETELY HUMAN MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-8 AND EPITOPES FOR SUCH ANTIBODIES |
WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
JP5457671B2 (ja) | 2005-07-28 | 2014-04-02 | ノバルティス アーゲー | M−csf特異的モノクローナル抗体およびその使用 |
EP1913028B1 (en) | 2005-07-28 | 2015-03-04 | Novartis AG | Use of antibody to m-csf |
PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
HUE025608T2 (en) * | 2005-09-07 | 2016-03-29 | Amgen Fremont Inc | Human monoclonal antibody against activin receptor-like kinase-1 (ALK-1) |
LT2655357T (lt) | 2010-12-20 | 2016-10-10 | Merck Serono S.A. | Indazolilo triazolo dariniai, kaip irak inhibitoriai |
KR101460477B1 (ko) | 2013-06-18 | 2014-11-10 | 주식회사 엘지화학 | 연신 적층체, 박형 편광자의 제조 방법, 이를 이용하여 제조되는 박형 편광자 및 이를 포함하는 편광판 |
JP6319584B2 (ja) | 2015-02-27 | 2018-05-09 | 京セラドキュメントソリューションズ株式会社 | 画像形成システム |
-
2004
- 2004-09-02 AR ARP040103147A patent/AR045563A1/es active IP Right Grant
- 2004-09-07 MY MYPI20043614A patent/MY157376A/en unknown
- 2004-09-08 TW TW098140349A patent/TWI365883B/zh not_active IP Right Cessation
- 2004-09-08 TW TW093127189A patent/TWI356063B/zh not_active IP Right Cessation
- 2004-09-09 HU HUE04809712A patent/HUE033708T2/en unknown
- 2004-09-09 NZ NZ595450A patent/NZ595450A/xx unknown
- 2004-09-09 CN CN200480028051XA patent/CN1863817B/zh not_active Expired - Fee Related
- 2004-09-09 KR KR1020067006880A patent/KR100899213B1/ko active IP Right Grant
- 2004-09-09 PE PE2004000873A patent/PE20050376A1/es active IP Right Grant
- 2004-09-09 ZA ZA200601969A patent/ZA200601969B/en unknown
- 2004-09-09 CN CN201210133918.4A patent/CN102807617B/zh not_active Expired - Fee Related
- 2004-09-09 PL PL04809712T patent/PL1670825T3/pl unknown
- 2004-09-09 UA UAA200603154A patent/UA90457C2/ru unknown
- 2004-09-09 AU AU2004275700A patent/AU2004275700B2/en not_active Ceased
- 2004-09-09 BR BRPI0414269A patent/BRPI0414269B8/pt not_active IP Right Cessation
- 2004-09-09 JP JP2006526276A patent/JP2007528724A/ja not_active Withdrawn
- 2004-09-09 EP EP04809712.5A patent/EP1670825B9/en active Active
- 2004-09-09 PT PT48097125T patent/PT1670825T/pt unknown
- 2004-09-09 SG SG200716760-4A patent/SG136945A1/en unknown
- 2004-09-09 NL NL1027009A patent/NL1027009C2/nl not_active IP Right Cessation
- 2004-09-09 GE GEAP20049338A patent/GEP20104922B/en unknown
- 2004-09-09 EA EA200600558A patent/EA011669B1/ru not_active IP Right Cessation
- 2004-09-09 KR KR1020087015841A patent/KR100938452B1/ko active IP Right Grant
- 2004-09-09 DK DK04809712.5T patent/DK1670825T3/en active
- 2004-09-09 US US10/938,353 patent/US7592430B2/en active Active
- 2004-09-09 MX MXPA06002825A patent/MXPA06002825A/es unknown
- 2004-09-09 EP EP16201588.7A patent/EP3170840B1/en active Active
- 2004-09-09 SI SI200432380T patent/SI1670825T1/sl unknown
- 2004-09-09 PA PA20048611701A patent/PA8611701A1/es unknown
- 2004-09-09 ES ES04809712.5T patent/ES2618526T3/es active Active
- 2004-09-09 NZ NZ584945A patent/NZ584945A/en unknown
- 2004-09-09 NZ NZ546369A patent/NZ546369A/en unknown
- 2004-09-09 WO PCT/US2004/029390 patent/WO2005030124A2/en active Application Filing
- 2004-09-09 SG SG2011081270A patent/SG176457A1/en unknown
- 2004-09-09 HN HN2004000356A patent/HN2004000356A/es unknown
- 2004-09-09 UY UY28507A patent/UY28507A1/es not_active Application Discontinuation
- 2004-09-09 ES ES16201588T patent/ES2709700T3/es active Active
- 2004-09-09 AP AP2006003562A patent/AP2006003562A0/xx unknown
- 2004-09-09 CA CA2885172A patent/CA2885172C/en not_active Expired - Fee Related
- 2004-09-09 GT GT200400181A patent/GT200400181A/es unknown
- 2004-09-09 GB GB0420044A patent/GB2405873A/en not_active Withdrawn
- 2004-09-09 RS YUP-2006/0171A patent/RS20060171A/sr unknown
- 2004-09-09 MX MX2012002136A patent/MX346194B/es unknown
- 2004-09-09 CA CA2537876A patent/CA2537876C/en not_active Expired - Fee Related
-
2006
- 2006-03-01 IL IL174016A patent/IL174016A/en active IP Right Grant
- 2006-03-07 IS IS8342A patent/IS3021B/is unknown
- 2006-03-10 TN TNP2006000080A patent/TNSN06080A1/en unknown
- 2006-03-13 US US11/375,221 patent/US7326414B2/en active Active
- 2006-03-28 CR CR8317A patent/CR8317A/es not_active Application Discontinuation
- 2006-04-07 NO NO20061603A patent/NO343557B1/no not_active IP Right Cessation
- 2006-04-10 MA MA28927A patent/MA28092A1/fr unknown
- 2006-04-10 EC EC2006006497A patent/ECSP066497A/es unknown
- 2006-12-20 HK HK06113986.3A patent/HK1093212A1/xx not_active IP Right Cessation
-
2007
- 2007-08-20 US US11/894,560 patent/US7728113B2/en not_active Expired - Fee Related
- 2007-10-09 JP JP2007263538A patent/JP2008067710A/ja active Pending
-
2010
- 2010-03-29 US US12/748,602 patent/US8188249B2/en active Active
-
2011
- 2011-01-21 JP JP2011010778A patent/JP2011083291A/ja active Pending
-
2012
- 2012-04-27 US US13/458,820 patent/US20120244167A1/en not_active Abandoned
-
2013
- 2013-06-04 HK HK13106536.3A patent/HK1178921A1/xx not_active IP Right Cessation
- 2013-07-16 JP JP2013147604A patent/JP5829653B2/ja not_active Expired - Fee Related
-
2015
- 2015-02-19 IL IL237323A patent/IL237323A0/en active IP Right Grant
- 2015-02-19 IL IL237324A patent/IL237324A0/en active IP Right Grant
- 2015-05-12 JP JP2015097050A patent/JP6106711B2/ja not_active Expired - Fee Related
- 2015-10-27 US US14/923,655 patent/US9718883B2/en active Active
-
2016
- 2016-10-18 JP JP2016204288A patent/JP6412903B2/ja not_active Expired - Fee Related
-
2017
- 2017-06-05 US US15/614,237 patent/US10280219B2/en active Active
-
2019
- 2019-03-15 US US16/354,615 patent/US20190202905A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100938452B1 (ko) | M-csf에 대한 항체 | |
CA2466128C (en) | Antibodies to cd40 | |
KR101865974B1 (ko) | β-KLOTHO, FGF 수용체 및 이들의 복합체에 결합하는 인간 항원 결합 단백질 | |
KR101527300B1 (ko) | 4-1bb 결합 분자 | |
CA2497884C (en) | Therapeutic human anti-il-1r1 monoclonal antibody | |
KR102551269B1 (ko) | 저-점도 항원 결합 단백질 및 이의 제조 방법 | |
KR101740615B1 (ko) | 인간 cgrp 수용체 결합 단백질 | |
US20030194404A1 (en) | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same | |
TW200523269A (en) | Antibodies to c-Met | |
KR20140076602A (ko) | 항-m-csf 항체를 사용한 염증성 장애의 치료 방법 | |
CA2496419A1 (en) | Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof | |
CN101124240A (zh) | 肝细胞生长因子的特异性结合物 | |
KR20150128982A (ko) | 인간 pac1 항체 | |
AU2019210504B2 (en) | Human antigen binding proteins that bind beta-Klotho, FGF receptors and complexes thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121227 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20131227 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20141226 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20151228 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170104 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20171229 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190103 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20191217 Year of fee payment: 11 |